English

RLS GLOBAL AB (publ) INTERIM REPORT, Q1, 2021

Report this content

JAN 1st – MARCH 31st

  • Net sales amounted to KSEK 50 (KSEK 374)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -6,3 (MSEK -3,9)
  • Earning per share before dilution at SEK -0,09 (SEK-0,06)
  • Cash flow from operating activities amounted to MSEK -5,8 (MSEK-4,2)
  • Liquid assets at the end of the period MSEK 13,2 (MSEK 35,9)
  • Equity ratio was 85% (92 %)
 

SUMMARY OF EVENTS DURING FIRST QUARTER

  • Both Lloyds and Eurofins (RLS’ notified bodies) have carried out quality audits of RLS Global without remarks. RLS Global is ready for and welcomes an MDR audit and review that will hopefully take place soon.
 

SUMMARY OF EVENTS AFTER FIRST QUARTER

  • ChloraSolv can now, after approval by the authorities, also be used on leg ulcers, which doubles the market potential.
 

COVID-19

  • In the current situation, the Board has considered the impact of different possible future covid-19 related scenarios.
  • Since the healthcare sector still is extremely strained under the prevailing circumstances, all processes take longer which affects RLS’ market penetration and other activities regarding ChloraSolv. RLS continues to have a strong focus on R&D related projects and to ensure good remuneration/reimbursement in important strategic markets in Europe.
     
 

TRADING PLACE AND CERTIFIED ADVISER
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.
 

CONTACT INFORMATION
Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 730 23 13 57


The Interim Report Q1, 2021 is enclosed and is also available at:
https://rls.global/wp-content/uploads/2021/05/RLS_Global_Q1_2021_EN.pdf
 

PUBLICATION
This information was submitted for publication through the agency of the above contact person,
at 09.00 CET on May 7th, 2021.

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. Read more at www.rls.global

Subscribe

Documents & Links